Formoterol Thrice Weekly Does Not Result in the Development of Tolerance to Bronchoprotection

Beth E Davis; John K Reid; Donald W Cockcroft

doi:10.1155/2003/148740

Canadian Respiratory Journal (Jan 2003)

Formoterol Thrice Weekly Does Not Result in the Development of Tolerance to Bronchoprotection

Beth E Davis,
John K Reid,
Donald W Cockcroft

Affiliations

Beth E Davis: Division of Respiratory Medicine, Department of Medicine, Royal University Hospital, Saskatoon, Saskatchewan, Canada
John K Reid: Division of Respiratory Medicine, Department of Medicine, Royal University Hospital, Saskatoon, Saskatchewan, Canada
Donald W Cockcroft: Division of Respiratory Medicine, Department of Medicine, Royal University Hospital, Saskatoon, Saskatchewan, Canada

DOI: https://doi.org/10.1155/2003/148740
Journal volume & issue: Vol. 10, no. 1
pp. 23 – 26

Abstract

Read online

BACKGROUND: Loss of bronchoprotection routinely follows regular treatment with beta2-agonists. There are no data on the effects on bronchoprotection for thrice weekly use of a beta2-agonist.

Published in Canadian Respiratory Journal

ISSN: 1198-2241 (Print); 1916-7245 (Online)
Publisher: Hindawi Limited
Country of publisher: United Kingdom
LCC subjects: Medicine: Internal medicine: Specialties of internal medicine: Diseases of the respiratory system
Website: https://onlinelibrary.wiley.com/journal/7503

About the journal